Table 1.
Baseline Demographic of the Study Cohort
| Clinical characteristics | COVID‐19, n=34 | Control, n=103 | P value* |
|---|---|---|---|
| Age, y, mean (SD) | 65.7 (9.1) | 66.7 (8.9) | NS |
| Women, n (%) | 13 (38.2) | 42 (41) | NS |
| Time from SARS‐CoV‐2 infection to cardiac PET, mo, median (IQR) | 4.6 (2.6–7.7) | NA | |
| Previously hospitalized for COVID‐19, n (%) | 15 (43) | NA | |
| Cardiovascular risk factors, n (%) | |||
| Obesity | 23 (67.7) | 71 (69) | NS |
| Diabetes | 19 (55.8) | 53 (51.5) | NS |
| Hypertension | 31 (91.2) | 92 (89.3) | NS |
| Dyslipidemia | 31 (91.2) | 89 (86.4) | NS |
| Known CAD | 10 (29.4) | 40 (38.8) | NS |
| Prior revascularization | 9 (26.4) | 33 (32) | 0.5 |
| Statin use | 32 (94) | 84/98 (86) | 0.2 |
Control subjects matched on age, sex, and cardiovascular risk factors (diabetes, hypertension, known CAD, obesity, dyslipidemia). CAD indicates coronary artery disease, and IQR, interquartile range.
*
P values represents conditional regression for dichotomous variables. P<0.05 is considered statistically significant.